-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Ovid Therapeutics, Lowers Price Target to $3

Benzinga·03/12/2025 14:27:05
Listen to the news
Wedbush analyst Laura Chico maintains Ovid Therapeutics (NASDAQ:OVID) with a Outperform and lowers the price target from $4 to $3.